CD19 CAR-T细胞治疗时无残留淋巴瘤的DLBCL患者毒性低且结局优异
该研究纳入8个学术中心33例在CD19 CAR-T输注时无可检测病灶的复发/难治性弥漫大B细胞淋巴瘤患者,中位随访16个月,1年无事件生存率和总生存率分别为59.6%和81.3%,无≥3级细胞因子释放综合征,仅1例发生4级神经毒性,提示完全缓解时输注可行、安全且疾病控制良好。
要点
- 33例CAR-T输注时无可检测病灶的R/R DLBCL患者中,无≥3级细胞因子释放综合征,仅1例4级神经毒性。
- 中位随访16个月,13例(39.4%)复发,6例(18.1%)死亡,1年无事件生存率59.6%、总生存率81.3%。
- 作者认为完全缓解时输注CAR-T可行、安全且疾病控制良好,需在更大临床试验中进一步探索。
核心结论
- 在适合CAR-T治疗的R/R DLBCL患者中,输注时处于完全缓解者接受治疗可行、安全且疾病控制良好,需在更大临床试验中进一步探索。
研究设计与样本
- 多中心研究,纳入8个学术中心33例在CD19 CAR-T细胞输注时无可检测病灶的复发/难治性弥漫大B细胞淋巴瘤患者。
- 9例接受阿基仑赛,24例接受替沙仑赛。
- 从白细胞分离到CAR-T输注的中位时间为48(19-193)天。
主要发现
- 无≥3级细胞因子释放综合征,仅1例发生4级神经毒性。
- 中位随访16个月,13例(39.4%)复发,6例(18.1%)死亡。
- 1年无事件生存率为59.6%,1年总生存率为81.3%。
临床怎么用
- 作者认为,对于有CAR-T治疗指征的R/R DLBCL患者,在输注时处于完全缓解状态进行治疗是可行、安全且与良好疾病控制相关的。
局限性
- 原文结论提出需在更大的临床试验环境中进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD19 chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), inducing sustained remissions in these patients. However, CAR T cells can result in significant toxicities. Preinfusion disease burden is associated with toxicities and outcomes after CAR T-cell therapy. We identified 33 patients with R/R DLBCL treated at 8 academic centers who had no detectable disease at the time of CAR T-cell therapy. The median time from leukapheresis to CAR T-cell infusion was 48 (19-193) days. Nine patients received axicabtagene ciloleucel, and 24 received tisagenlecleucel. There was no severe (grade ≥3) cytokine release syndrome, and only 1 patient developed severe neurotoxicity (grade 4). After a median follow-up of 16 months, 13 patients relapsed (39.4%) and 6 died (18.1%). One-year event-free survival and overall survival were 59.6% and 81.3%, respectively. Our findings suggest that, in patients with R/R DLBCL who have an indication for CAR T-cell therapy, treating patients in complete remission at the time of infusion is feasible, safe, and associated with favorable disease control. Further exploration in a larger clinical trial setting is warranted.
引用
- Wudhikarn K, Tomas AA, Flynn JR, et al. Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. Blood Adv. 2023. PMID: 36355838. doi:10.1182/bloodadvances.2022008294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。